| 1 | Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies. (Bal S, Estrada-Merly N, Costa LJ, Qazilbash MH, Kumar S, D'Souza A) Blood Cancer J 2023 Nov 15;13(1):170 7 Citations |
| 1 | Efficacy of a prolonged stability melphalan formulation for intra-arterial treatment of retinoblastoma. (Jubran JH, Luong H, Naik A, Srinivasan VM, Ramasubramanian A, Li A, Scherschinski L, Feldman MJ, Albuquerque FC, Abruzzo TA) J Neurointerv Surg 2024 May 21;16(6):572-577 1 Citation |
| 2 | Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT. (Geerlinks AV, Scull B, Krupski C, Fleischmann R, Pulsipher MA, Eapen M, Connelly JA, Bollard CM, Pai SY, Duncan CN, Kean LS, Baker KS, Burroughs LM, Andolina JR, Shenoy S, Roehrs P, Hanna R, Talano JA, Schultz KR, Stenger EO, Lin H, Zoref-Lorenz A, McClain KL, Jordan MB, Man TK, Allen CE, Marsh RA) Blood Adv 2023 Jul 25;7(14):3725-3734 4 Citations |
| 1 | Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. (Ragon BK, Shah MV, D'Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, Banerjee R, Saad A, Hildebrandt GC, Mian H, Abid MB, Battiwalla M, Lekakis LJ, Patel SS, Murthy HS, Nieto Y, Strouse C, Badawy SM, Al Hadidi S, Dholaria B, Aljurf M, Vesole DH, Lee CH, Pawarode A, Gergis U, Miller KC, Holmberg LA, Afrough A, Solh M, Munshi PN, Nishihori T, Anderson LD Jr., Wirk B, Kaur G, Qazilbash MH, Shah N, Kumar SK, Usmani SZ) Blood Adv 2023 Jun 27;7(12):2746-2757 27 Citations |
| 2 | Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. (Murthy GSG, Kim S, Estrada-Merly N, Abid MB, Aljurf M, Assal A, Badar T, Badawy SM, Ballen K, Beitinjaneh A, Cerny J, Chhabra S, DeFilipp Z, Dholaria B, Perez MAD, Farhan S, Freytes CO, Gale RP, Ganguly S, Gupta V, Grunwald MR, Hamad N, Hildebrandt GC, Inamoto Y, Jain T, Jamy O, Juckett M, Kalaycio M, Krem MM, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Ortí G, Patel SS, Van der Poel M, Rizzieri DA, Savani BN, Seo S, Solh M, Verdonck LF, Wirk B, Yared JA, Nakamura R, Oran B, Scott B, Saber W) Haematologica 2023 Jul 01;108(7):1900-1908 24 Citations |
| 1 | A Review of Propylene Glycol-free Melphalan Conditioning for Hematopoietic Cell Transplantation for Multiple Myeloma and Light Chain Amyloidosis. (Hari P, Chhabra S) Transplant Cell Ther 2022 May;28(5):242-247 3 Citations |
| 2 | Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. (Oran B, Ahn KW, Fretham C, Beitinjaneh A, Bashey A, Pawarode A, Wirk B, Scott BL, Savani BN, Bredeson C, Weisdorf D, Marks DI, Rizzieri D, Copelan E, Hildebrandt GC, Hale GA, Murthy HS, Lazarus HM, Cerny J, Liesveld JL, Yared JA, Yves-Cahn J, Szer J, Verdonck LF, Aljurf M, van der Poel M, Litzow M, Kalaycio M, Grunwald MR, Diaz MA, Sabloff M, Kharfan-Dabaja MA, Majhail NS, Farhadfar N, Reshef R, Olsson RF, Gale RP, Nakamura R, Seo S, Chhabra S, Hashmi S, Farhan S, Ganguly S, Nathan S, Nishihori T, Jain T, Agrawal V, Bacher U, Popat U, Saber W) Transplant Cell Ther 2021 Nov;27(11):921.e1-921.e10 28 Citations |
| 2 | Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older. (Munshi PN, Vesole DH, St Martin A, Davila O, Kumar S, Qazilbash M, Shah N, Hari PN, D'Souza A) Cancer 2021 Nov 15;127(22):4233-4239 16 Citations |
| 2 | Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders. (Marsh RA, Hebert K, Kim S, Dvorak CC, Aquino VM, Baker KS, Chellapandian D, Dávila Saldaña B, Duncan CN, Eckrich MJ, Georges GE, Olson TS, Pulsipher MA, Shenoy S, Stenger E, Lugt MV, Yu LC, Gennery AR, Eapen M) J Allergy Clin Immunol 2022 Mar;149(3):1097-1104.e2 36 Citations |
| 1 | Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. (Granger MM, Naranjo A, Bagatell R, DuBois SG, McCune JS, Tenney SC, Weiss BD, Mosse YP, Asgharzadeh S, Grupp SA, Hogarty MD, Gastier-Foster JM, Mills D, Shulkin BL, Parisi MT, London WB, Han-Chang J, Panoff J, von Allmen D, Jarzembowski JA, Park JR, Yanik GA) Transplant Cell Ther 2021 Jun;27(6):490.e1-490.e8 29 Citations |
| 2 | Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. (Myllymäki M, Redd R, Reilly CR, Saber W, Spellman SR, Gibson CJ, Hu ZH, Wang T, Orr EH, Grenier JG, Chen MM, Steensma DP, Cutler C, De Vivo I, Antin JH, Neuberg D, Agarwal S, Lindsley RC) Blood 2020 Dec 24;136(26):3070-3081 46 Citations |
| 2 | Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. (Munshi PN, Vesole D, Jurczyszyn A, Zaucha JM, St Martin A, Davila O, Agrawal V, Badawy SM, Battiwalla M, Chhabra S, Copelan E, Kharfan-Dabaja MA, Farhadfar N, Ganguly S, Hashmi S, Krem MM, Lazarus HM, Malek E, Meehan K, Murthy HS, Nishihori T, Olin RL, Olsson RF, Schriber J, Seo S, Shah G, Solh M, Tay J, Kumar S, Qazilbash MH, Shah N, Hari PN, D'Souza A) Cancer 2020 Dec 01;126(23):5077-5087 64 Citations |
| 4 | Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma. (Monahan K, Kleman A, Thapa B, Szabo A, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Hamadani M, Hari PN, Chhabra S) Biol Blood Marrow Transplant 2020 Dec;26(12):2229-2236 5 Citations |
| 2 | Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen. (Hagen P, D'Souza A, Hari P, Davila O, Zhang MJ, Vesole DH, Smith SE, Rodriguez TE, Stiff PJ) Leuk Lymphoma 2020 Dec;61(14):3484-3492 4 Citations |
| 4 | Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. (Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, Ahmed G, Al-Homsi AS, Aljurf M, Alkhateeb HB, Assal A, Bacher U, Bajel A, Bashir Q, Battiwalla M, Bhatt VR, Byrne M, Cahn JY, Cairo M, Choe H, Copelan E, Cutler C, Damlaj MB, DeFilipp Z, De Lima M, Diaz MA, Farhadfar N, Foran J, Freytes CO, Gerds AT, Gergis U, Grunwald MR, Gul Z, Hamadani M, Hashmi S, Hertzberg M, Hildebrandt GC, Hossain N, Inamoto Y, Isola L, Jain T, Kamble RT, Khan MW, Kharfan-Dabaja MA, Kebriaei P, Kekre N, Khera N, Lazarus HM, Liesveld JL, Litzow M, Liu H, Marks DI, Martino R, Mathews V, Mishra A, Murthy HS, Nagler A, Nakamura R, Nathan S, Nishihori T, Olin R, Olsson RF, Palmisiano N, Patel SS, Patnaik MM, Pawarode A, Perales MA, Politikos I, Popat U, Rizzieri D, Sandmaier BM, Savani BN, Seo S, Shah NN, Uy GL, Valcárcel D, Verdonck LF, Waller EK, Wang Y, Weisdorf D, Wirk B, Wong E, Yared JA, Saber W) Blood Adv 2020 Jul 14;4(13):3180-3190 27 Citations |
| 2 | Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. (Ghosh N, Ahmed S, Ahn KW, Khanal M, Litovich C, Aljurf M, Bacher VU, Bredeson C, Epperla N, Farhadfar N, Freytes CO, Ganguly S, Haverkos B, Inwards D, Kamble RT, Lazarus HM, Lekakis L, Murthy HS, Nishihori T, Ramakrishnan P, Rizzieri DA, Yared JA, Kharfan-Dabaja MA, Sureda A, Hamadani M) JAMA Oncol 2020 Jul 01;6(7):1011-1018 53 Citations |
| 2 | Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. (Ahmed S, Ghosh N, Ahn KW, Khanal M, Litovich C, Mussetti A, Chhabra S, Cairo M, Mei M, William B, Nathan S, Bejanyan N, Olsson RF, Dahi PB, van der Poel M, Steinberg A, Kanakry J, Cerny J, Farooq U, Seo S, Kharfan-Dabaja MA, Sureda A, Fenske TS, Hamadani M) Br J Haematol 2020 Aug;190(4):573-582 30 Citations |
| 2 | Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. (Jagadeesh D, Majhail NS, He Y, Ahn KW, Litovich C, Ahmed S, Aljurf M, Bacher U, Badawy SM, Bejanyan N, Cairo M, Cerny J, Epperla N, Farhadfar N, Freytes CO, Gale RP, Haverkos B, Hossain N, Inwards D, Kamble RT, Kenkre VP, Lazarus HM, Lazaryan A, Lekakis L, Mei M, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Ramakrishnan Geethakumari P, Savani BN, Yared JA, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M) Cancer 2020 May 15;126(10):2279-2287 23 Citations |
| 2 | Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation. (Herr MM, Curtis RE, Tucker MA, Tecca HR, Engels EA, Cahoon EK, Battiwalla M, Buchbinder D, Flowers ME, Brazauskas R, Shaw BE, Morton LM) J Am Acad Dermatol 2020 Sep;83(3):762-772 13 Citations |
| 1 | Surface-Modified Melphalan Nanoparticles for Intravitreal Chemotherapy of Retinoblastoma. (Sims LB, Tyo KM, Stocke S, Mahmoud MY, Ramasubramanian A, Steinbach-Rankins JM) Invest Ophthalmol Vis Sci 2019 Apr 01;60(5):1696-1705 30 Citations |
| 1 | BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas. (Singer S, Sharma N, Dean R, Zhao Q, Abounader D, Elder P, Hofmeister CC, Benson DM, Rosko A, Penza S, Andritsos L, Vasu S, Jaglowski S, William BM, Bolwell B, Pohlman B, Kalaycio M, Jagadeesh D, Hill B, Sobecks R, Devine SM, Majhail NS, Efebera YA) Bone Marrow Transplant 2019 Oct;54(10):1553-1561 8 Citations |
| 1 | BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma. (Singer S, Dean R, Zhao Q, Sharma N, Abounader D, Elder P, Hofmeister CC, Benson DM, Rosko A, Penza S, Andritsos L, Vasu S, Jaglowski S, William BM, Bolwell B, Pohlman B, Kalaycio M, Jagadeesh D, Hill B, Sobecks R, Devine SM, Majhail NS, Efebera YA) Biol Blood Marrow Transplant 2019 Jun;25(6):1107-1115 11 Citations |
| 2 | Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. (Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Giralt S, Somlo G, Krishnan A) J Clin Oncol 2019 Mar 01;37(7):589-597 234 Citations |
| 2 | Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. (Allen CE, Marsh R, Dawson P, Bollard CM, Shenoy S, Roehrs P, Hanna R, Burroughs L, Kean L, Talano JA, Schultz KR, Pai SY, Baker KS, Andolina JR, Stenger EO, Connelly J, Ramirez A, Bryant C, Eapen M, Pulsipher MA) Blood 2018 Sep 27;132(13):1438-1451 95 Citations |
| 1 | Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival. (Hari P, Reece DE, Randhawa J, Flomenberg N, Howard DS, Badros AZ, Rapoport AP, Meisenberg BR, Filicko-Ohara J, Phillips GL, Vesole DH) Bone Marrow Transplant 2019 Feb;54(2):293-299 11 Citations |
| 4 | Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. (Dhakal B, D'Souza A, Lakshman A, Hamadani M, Chhabra S, Thompson R, Shah N, Pasquini M, Hari P) Biol Blood Marrow Transplant 2018 Aug;24(8):1610-1614 9 Citations |
| 8 | Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. (Badar T, Hari P, Chhabra S, Dhakal B, Drobyski WR, Fenske TS, Hamadani M, Pasquini M, Saber W, Shah NN, Shaw BE, D'Souza A) Bone Marrow Transplant 2018 Sep;53(9):1210-1213 7 Citations |
| 2 | Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. (Costa LJ, Landau HJ, Chhabra S, Hari P, Innis-Shelton R, Godby KN, Hamadani M, Tamari R, Anderton K, Dixon P, Giralt SA) Biol Blood Marrow Transplant 2018 Jul;24(7):1379-1385 18 Citations |
| 2 | Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. (Mahindra A, Hari P, Fraser R, Fei M, Huang J, Berdeja J, Callander N, Costa L, Diaz MA, Freytes C, Gale RP, Girnius S, Holmberg L, Kharfan-Dabaja M, Kumar S, Kyle R, Lazarus H, Lee C, Maiolino A, Moreb J, Nishihori T, Pawarode A, Saad A, Savani BN, Schriber J, William B, Wirk BM, Krishnan A, Nieto Y, D'Souza A) Bone Marrow Transplant 2017 Dec;52(12):1616-1622 54 Citations |
| 1 | A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. (Dispenzieri A, D'Souza A, Gertz MA, Laumann K, Wiseman G, Lacy MQ, LaPlant B, Buadi F, Hayman SR, Kumar SK, Dingli D, Hogan WJ, Ansell SM, Gastineau DA, Inwards DJ, Micallef IN, Porrata LF, Johnston PB, Litzow MR, Witzig TE) Bone Marrow Transplant 2017 Oct;52(10):1372-1377 13 Citations |
| 3 | Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. (Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME) J Clin Oncol 2017 Apr 10;35(11):1154-1161 591 Citations |
| 5 | Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. (Dhakal B, Nelson A, Guru Murthy GS, Fraser R, Eastwood D, Hamadani M, Pasquini M, D'Souza A, Hari P) Clin Lymphoma Myeloma Leuk 2017 Mar;17(3):165-172 20 Citations |
| 1 | Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. (Rodriguez TE, Hari P, Stiff PJ, Smith SE, Sterrenberg D, Vesole DH) Biol Blood Marrow Transplant 2016 Aug;22(8):1391-1396 31 Citations |
| 2 | New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation. (D'Souza A, Huang J, Hari P) Biol Blood Marrow Transplant 2016 Apr;22(4):768-770 6 Citations |
| 1 | Ocular dysmotility after intra-arterial chemotherapy for retinoblastoma. (Lambert NG, Winegar BA, Feola GP, Ramasubramanian A) J AAPOS 2015 Dec;19(6):574-7 8 Citations |
| 3 | Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. (D'Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, Kyle RA, Kumar S, Comenzo RL, Peter Gale R, Lazarus HM, Savani BN, Cornell RF, Weiss BM, Vogl DT, Freytes CO, Scott EC, Landau HJ, Moreb JS, Costa LJ, Ramanathan M, Callander NS, Kamble RT, Olsson RF, Ganguly S, Nishihori T, Kindwall-Keller TL, Wood WA, Mark TM, Hari P) J Clin Oncol 2015 Nov 10;33(32):3741-9 186 Citations |
| 1 | A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation. (Hari P, Aljitawi OS, Arce-Lara C, Nath R, Callander N, Bhat G, Allen LF, Stockerl-Goldstein K) Biol Blood Marrow Transplant 2015 Dec;21(12):2100-2105 30 Citations |
| 2 | Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. (Chen YB, Lane AA, Logan B, Zhu X, Akpek G, Aljurf M, Artz A, Bredeson CN, Cooke KR, Ho VT, Lazarus HM, Olsson R, Saber W, McCarthy P, Pasquini MC) Biol Blood Marrow Transplant 2015 Jun;21(6):1046-1053 145 Citations |
| 1 | Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. (Bechtel T, McBride A, Crawford B, Bullington S, Hofmeister CC, Benson DM Jr, Jaglowski S, Penza S, Andritsos LA, Devine SM) Support Care Cancer 2014 Nov;22(11):2911-6 18 Citations |
| 4 | Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. (Saad A, Mahindra A, Zhang MJ, Zhong X, Costa LJ, Dispenzieri A, Drobyski WR, Freytes CO, Gale RP, Gasparetto CJ, Holmberg LA, Kamble RT, Krishnan AY, Kyle RA, Marks D, Nishihori T, Pasquini MC, Ramanathan M, Lonial S, Savani BN, Saber W, Sharma M, Sorror ML, Wirk BM, Hari PN) Biol Blood Marrow Transplant 2014 Mar;20(3):402-408.e1 99 Citations |
| 1 | Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. (Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, Stadtmauer EA, Mineshi S, Ambinder R, Fenske T, Horowitz M, Fisher R, Tomblyn M) J Clin Oncol 2013 May 01;31(13):1662-8 143 Citations |
| 1 | Intra-arterial chemotherapy for retinoblastoma: report No. 2, treatment complications. (Shields CL, Bianciotto CG, Jabbour P, Griffin GC, Ramasubramanian A, Rosenwasser R, Shields JA) Arch Ophthalmol 2011 Nov;129(11):1407-15 158 Citations |
| 1 | Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. (Shields CL, Bianciotto CG, Jabbour P, Ramasubramanian A, Lally SE, Griffin GC, Rosenwasser R, Shields JA) Arch Ophthalmol 2011 Nov;129(11):1399-406 215 Citations |
| 2 | Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. (Vogl DT, Wang T, Pérez WS, Stadtmauer EA, Heitjan DF, Lazarus HM, Kyle RA, Kamble R, Weisdorf D, Roy V, Gibson J, Ballen K, Holmberg L, Bashey A, McCarthy PL, Freytes C, Maharaj D, Maiolino A, Vesole D, Hari P) Biol Blood Marrow Transplant 2011 Dec;17(12):1765-74 49 Citations |
| 1 | The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. (Marks DI, Wang T, Pérez WS, Antin JH, Copelan E, Gale RP, George B, Gupta V, Halter J, Khoury HJ, Klumpp TR, Lazarus HM, Lewis VA, McCarthy P, Rizzieri DA, Sabloff M, Szer J, Tallman MS, Weisdorf DJ) Blood 2010 Jul 22;116(3):366-74 173 Citations |
| 1 | Superselective catheterization of the ophthalmic artery for intraarterial chemotherapy for retinoblastoma. (Shields CL, Ramasubramanian A, Rosenwasser R, Shields JA) Retina 2009 Sep;29(8):1207-9 40 Citations |
| 1 | Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma. (Chang JE, Juckett MB, Callander NS, Kahl BS, Gangnon RE, Mitchell TL, Longo WL) Clin Lymphoma Myeloma 2008 Jun;8(3):153-8 5 Citations |
| 1 | Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. (Ingram W, Devereux S, Das-Gupta EP, Russell NH, Haynes AP, Byrne JL, Shaw BE, McMillan A, Gonzalez J, Ho A, Mufti GJ, Pagliuca A) Br J Haematol 2008 Apr;141(2):235-43 43 Citations |
| 1 | Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma. (Williams KM, Higman MA, Chen AR, Schwartz CL, Wharam M, Colombani P, Arceci RJ) Pediatr Blood Cancer 2008 Mar;50(3):667-70 23 Citations |
| 1 | Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. (Kröger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, Nagler A, Binder T, Eiermann T, Madrigal A, Schwerdtfeger R, Kiehl M, Sayer HG, Beyer J, Bornhäuser M, Ayuk F, Zander AR, Marks DI, Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group) Br J Haematol 2005 Jun;129(5):631-43 105 Citations |
| 1 | Pancytopenia responding to treatment of hyperthyroidism: a clinical case and review of the literature. (Shaw B, Mehta AB) Clin Lab Haematol 2002 Dec;24(6):385-7 20 Citations |
| 1 | L-amino acid oxidase (LOX) modulation of melphalan activity against intracranial glioma. (Moynihan K, Elion GB, Pegram C, Reist CJ, Wellner D, Bigner DD, Griffith OW, Friedman HS) Cancer Chemother Pharmacol 1997;39(3):179-86 7 Citations |
| 1 | High-dose melphalan +/- total body irradiation and autologous hematopoietic stem cell rescue for adult patients with Ewing's sarcoma or peripheral neuroectodermal tumor. (Stewart DA, Gyonyor E, Paterson AH, Arthur K, Temple W, Schachar NS, Klassen J, Brown C, Russell JA) Bone Marrow Transplant 1996 Aug;18(2):315-8 38 Citations |
| 1 | High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study. (Mahoney DH Jr, Strother D, Camitta B, Bowen T, Ghim T, Pick T, Wall D, Yu L, Shuster JJ, Friedman H) J Clin Oncol 1996 Feb;14(2):382-8 115 Citations |
| 1 | Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats. (Kurpad SN, Friedman HS, Archer GE, McLendon RE, Petros WM, Fuchs HE, Guaspari A, Bigner DD) Cancer Res 1995 Sep 01;55(17):3803-9 13 Citations |
| 1 | Circumvention of confluence-dependent resistance in a human multi-drug-resistant colon-cancer cell line. (Garrido C, Chauffert B, Pinard D, Tibaut F, Genne P, Assem M, Dimanche-Boitrel MT) Int J Cancer 1995 Jun 09;61(6):873-9 24 Citations |
| 1 | The effect of L-amino acid oxidase on activity of melphalan against an intracranial xenograft. (Rich JN, Elion GB, Wellner D, Colvin OM, Groothuis DR, Hilton JH, Schlageter KE, Bigner DD, Griffith OW, Friedman HS) Cancer Chemother Pharmacol 1995;36(5):379-84 5 Citations |
| 1 | Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. (Friedman HS, Dolan ME, Kaufmann SH, Colvin OM, Griffith OW, Moschel RC, Schold SC, Bigner DD, Ali-Osman F) Cancer Res 1994 Jul 01;54(13):3487-93 54 Citations |
| 1 | Development of a model of melphalan-induced gastrointestinal toxicity in mice. (Castellino S, Elion GB, Griffith OW, Dewhirst M, Kurtzberg J, Cattley RC, Scott P, Bigner DD, Friedman HS) Cancer Chemother Pharmacol 1993;31(5):376-80 12 Citations |
| 1 | Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft. (Laskowitz DT, Elion GB, Dewhirst MW, Griffith OW, Savina PM, Blum MR, Prescott DM, Bigner DD, Friedman HS) Radiat Res 1992 Feb;129(2):218-23 16 Citations |
| 1 | Enhancement of melphalan-induced gastrointestinal toxicity in mice treated with regional hyperthermia and BSO-mediated glutathione depletion. (Laskowitz DT, Elion GB, Dewhirst MW, Griffith OW, Cattley RC, Bigner DD, Friedman HS) Int J Hyperthermia 1992;8(1):111-20 5 Citations |
| 1 | Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine. (Skapek SX, VanDellen AF, McMahon DP, Postels DG, Griffith OW, Bigner DD, Friedman HS) Cancer Chemother Pharmacol 1991;28(1):15-21 12 Citations |
| 1 | High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: a Pediatric Oncology Group study. (Pole JG, Casper J, Elfenbein G, Gee A, Gross S, Janssen W, Koch P, Marcus R, Pick T, Shuster J) J Clin Oncol 1991 Jan;9(1):152-8 125 Citations |
| 1 | Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion. (Rosenberg MC, Colvin OM, Griffith OW, Bigner SH, Elion GB, Horton JK, Lilley E, Bigner DD, Friedman HS) Cancer Res 1989 Dec 15;49(24 Pt 1):6917-22 29 Citations |
| 1 | Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion. (Friedman HS, Colvin OM, Griffith OW, Lippitz B, Elion GB, Schold SC Jr, Hilton J, Bigner DD) J Natl Cancer Inst 1989 Apr 05;81(7):524-7 35 Citations |
| 1 | Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice. (Skapek SX, Colvin OM, Griffith OW, Elion GB, Bigner DD, Friedman HS) Cancer Res 1988 May 15;48(10):2764-7 57 Citations |
